Dr. Eric K. Singhi shares his insights into the advantages of the subcutaneous formulation of Opdivo versus the IV version ...
Dr. Balazs Halmos discusses the significance of the approval of subcutaneous Opdivo and what this treatment formulation means ...
Subcutaneous nivolumab and hyaluronidase-nvhy is FDA-approved for adult solid tumors, offering a new administration route for PD-1 inhibitors. The phase 3 CheckMate-67T trial confirmed ...
These tumors can arise de novo or can be associated with other myeloid disorders -- acute myeloid leukemia (AML) or CML, myeloproliferative, or myelodysplastic conditions. Presentation can occur ...
which can comprise up to 25 percent of the tumor’s mass. Myeloid cells invade tumors in response to diverse inflammatory stimuli produced by the tumor. Invading myeloid cells differentiate into ...
The U.S. Food and Drug Administration has approved Opdivo Qvantig (nivolumab and hyaluronidase-nvhy) injection for subcutaneous use for most previously approved adult, solid tumor Opdivo ...
A research team made a pivotal discovery in the field of cancer immunotherapy. The team identified a specific population of immune cells that play a critical role in successful treatment of relapsed ...
Kineta is leveraging its deep expertise in innate immunity, and particularly myeloid cells, to develop innovative, first-in-class therapies with a primary focus on cancer. To date, immune-based ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback